Abstract
Efficacy and toxicity of Am (600 mg/M2/d IV) and Ti (12 gm/M2/d IV) as empiric therapy were evaluated in 46 febrile neutropenic (≤1000 PMNs/mm3) children with cancer. Documented infection (DI), clinically apparent infection (CA), possible infection (PI) and doubtful infections (DOI) were evaluated as follows:
Bacterial pathogens identified were E. coli-5, P. aeurginosa-2, Klebsiella sp.-2, Serratia sp-1, Staph. sp.-5 and Strep. sp.-1. The 4 non-responders did not have documented infections. Blood urea nitrogen, creatinine, creatinine clearance, potassium and urine analysis obtained before and after antibiotic therapy showed no significant differences. Comparisons of mean peak/trough serum levels of Am obtained on day 2 (23.9/< 2μg/ml) and day 5 (24.2/< 2μg/ml) showed no accumulation. Two of 23 paired audiograms obtained early in the course of and after Am therapy showed transient mild high frequency hearing loss. Am and Ti have low toxicity, are well tolerated and are adequate empiric therapy for the febrile neutropenic child.
Log in or create a free account to read this content
Gain free access to this article, as well as selected content from this journal and more on nature.com
or
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Deshpande, G., Faden, H., Grossi, M. et al. 805 AMIKACIN (AM) AND TICARCILLIN (TI) AS EMPIRIC THERAPY IN FEBRILE NEOTROPENIC CHILDREN WITH CANCER. Pediatr Res 15 (Suppl 4), 576 (1981). https://doi.org/10.1203/00006450-198104001-00829
Issue date:
DOI: https://doi.org/10.1203/00006450-198104001-00829
